<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">126</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:7099c1e0-efdc-54e4-93b7-b6ecd3612deb</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Bulgarian Society of Medical Sciences Journal</journal-title>
        <abbrev-journal-title xml:lang="en">BSMS</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2815-4959</issn>
      <issn pub-type="epub">3033-1471</issn>
      <publisher>
        <publisher-name>Nora 2000</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/bsms.7.144070</article-id>
      <article-id pub-id-type="publisher-id">144070</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Paraclinical</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>﻿Oxidative stress and neuroregenerative processes – pathophysiological correlations and new pharmacotherapeutic approaches in the treatment of neuroregenerative diseases</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Ivanova</surname>
            <given-names>Stefka</given-names>
          </name>
          <email xlink:type="simple">ivanovastefka_pharm@yahoo.com</email>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Obreshkova</surname>
            <given-names>Danka</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Atanasov</surname>
            <given-names>Petar</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0006-8337-2089</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Mladenov</surname>
            <given-names>Boris</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-4219-1231</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Atanasova</surname>
            <given-names>Venceslava</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Ibrahim</surname>
            <given-names>Adel</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Bulgarian Pharmaceutical Science Society, Sofia, Bulgaria</addr-line>
        <institution>Bulgarian Pharmaceutical Science Society</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, Sofia, Bulgaria, Sofia, Bulgaria.</addr-line>
        <institution>University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Stefka Ivanova, Bulgarian Pharmaceutical Science Society, 2 Dunav Str., Sofia, Bulgaria; E-mail: <email xlink:type="simple">ivanovastefka_pharm@yahoo.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2025</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>04</month>
        <year>2025</year>
      </pub-date>
      <volume>7</volume>
      <elocation-id>e144070</elocation-id>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/0D7D7FC2-5B0C-5F9B-A204-E4ED3FD3F15E">0D7D7FC2-5B0C-5F9B-A204-E4ED3FD3F15E</uri>
      <uri content-type="zenodo_dep_id" xlink:href="https://zenodo.org/record/15201530">15201530</uri>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>12</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>12</month>
          <year>2024</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Stefka Ivanova, Danka Obreshkova, Petar Atanasov, Boris Mladenov, Venceslava Atanasova, Adel Ibrahim</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>﻿Abstract</label>
        <p>The aims of the current study are estimation of the correlations between oxidative stress and neuroregenerative processes and new pharmacotherapeutic approaches in the treatment of Parkinsonism. The investigation has been made through the existing electronical database of medical sources. Oxidative stress arises from an increased production of reactive oxygen/nitrogen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0ELE">ROS</abbrev>/<abbrev xlink:title="reactive nitrogen species" id="ABBRID0EPE">RNS</abbrev>) or from a failure of the body’s antioxidant defenses, characterized by a reduced ability of endogenous systems to combat the oxidative attack directed at target biomolecules. It is broadly defined as a lack of balance between the levels of reactive oxygen/nitrogen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0ETE">ROS</abbrev>/<abbrev xlink:title="reactive nitrogen species" id="ABBRID0EXE">RNS</abbrev>) and the body’s ability to counteract their effect through antioxidant defence systems. Free-radical induced attack has been associated with the onset of numerous health conditions such as neurodegenerative diseases (Parkinson’s, Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis), cardiovascular and inflammatory diseases. In addition, the irreversible progression of oxidative deposition caused by reactive oxygen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0E2E">ROS</abbrev>) leads to accelerated biological aging, blocked biological functions, and overall. Other risk factors for neuroregenerative processes are glutamate toxicity, autoimmune, protein aggregation, inflammation. The most severe motor neuron degenerative illness is Amyotrophic Lateral Sclerosis (<abbrev xlink:title="Amyotrophic Lateral Sclerosis" id="ABBRID0E6E">ALS</abbrev>, Lou Gehrig’s disorder).</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>Oxidative stress</kwd>
        <kwd>neuroregenerative processes</kwd>
        <kwd>parkinsonism</kwd>
        <kwd>Alzheimer’s disease</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="SECID0EKF">
        <title>Citation</title>
        <p>Ivanova S, Obreshkova D, Atanasov P, Mladenov B, Atanasova V, Ibrahim A. Oxidative stress and neuroregenerative processes - pathophysiological correlations and new pharmacotherapeutic approaches in the treatment of neuroregenerative diseases. Bulgarian Society of Medical Sciences Journal 2025;7:e144070. doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3897/bsms.7.144070">10.3897/bsms.7.144070</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="﻿Oxidative stress" id="SECID0EWF">
      <title>﻿Oxidative stress</title>
      <p>Oxidative stress underlies the pathogenesis of aging and a number of diseases. The brain is particularly sensitive to the effects of free radicals due to high oxygen consumption, the presence of unsaturated fatty acids, and reduced activity of oxidation-sensitive endogenous antioxidant systems. In Alzheimer’s disease, oxidative stress occurs as a result of a disturbance in the balance between endogenous or exogenous overproduction of reactive oxygen species and a decrease in antioxidant defence mechanisms <sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>.</p>
    </sec>
    <sec sec-type="﻿General Characteristics of Oxidative stress" id="SECID0EDG">
      <title>﻿General Characteristics of Oxidative stress</title>
      <p>Free radicals have high reactivity due to the presence of unpaired electrons in their structure. Free-radical processes damage intracellular, extracellular and membrane biomacromolecules: proteins, lipids, nucleic acids (DNA, RNA), thereby interfering with the transmission of intracellular signals, leading to the formation of toxins, tissue damage, alteration of the redox state of cells and cell death (apoptosis). Reactive particles are the cause of pathogenetic changes and the development of pathological processes in many diseases <sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup>.</p>
      <p>Oxidative stress results from an imbalance between the body’s antioxidant defense mechanisms and the increased formation of reactive species: superoxide, hydroxyl, hydroperoxyl, alkoxyl, peroxyl, peroxynitrite radicals <sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup>.</p>
      <p>Research in the field of coordination compounds is directed towards the design of metal complexes of various biologically active organic ligands, which have practical applications in medicine and pharmacy in the therapy of various diseases. Oxidative stress underlies the pathogenesis of aging and in the etiology and neurodegeneration in neurodegenerative diseases such as Huntington‘s, Alzheimer‘s, and Parkinson‘s diseases, Lowe-Gerich (amyotrophic lateral sclerosis), multiple sclerosis and is the cause of the progression of schizophrenia, depression, autism, attention deficit hyperactivity disorder and chronic fatigue syndrome. Oxidative stress was first characterized by Sies as “a disturbance in the prooxidant and antioxidant balance that leads to potential damage. It is broadly defined as a lack of balance between the levels of reactive oxygen/nitrogen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0E2G">ROS</abbrev>/<abbrev xlink:title="reactive nitrogen species" id="ABBRID0E6G">RNS</abbrev>) and the body’s ability to counteract their effect through antioxidant defence systems <sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>. Oxidative stress arises from an increased production of <abbrev xlink:title="reactive oxygen species" id="ABBRID0EKH">ROS</abbrev> and/or <abbrev xlink:title="reactive nitrogen species" id="ABBRID0EOH">RNS</abbrev> species or from a failure of the body’s antioxidant defenses, characterized by a reduced ability of endogenous systems to combat the oxidative attack directed at target biomolecules. Free-radical induced attack has been associated with the onset of numerous health conditions such as neurodegenerative diseases (Parkinson’s, Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis), cardiovascular and inflammatory diseases. In addition, the irreversible progression of oxidative deposition caused by reactive oxygen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0ESH">ROS</abbrev>) leads to accelerated biological aging, blocked biological functions, and overall, reduced life span<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup>.</p>
    </sec>
    <sec sec-type="﻿Reactive oxygen species (ROS) and reactive nitrogen species (RNS)" id="SECID0E4H">
      <title>﻿Reactive oxygen species (ROS) and reactive nitrogen species (<abbrev xlink:title="reactive nitrogen species" id="ABBRID0EHAAC">RNS</abbrev>)</title>
      <p>Reactive oxygen species (<abbrev xlink:title="reactive oxygen species" id="ABBRID0ENAAC">ROS</abbrev>) (or also called free radicals) were first described by Fenton in 1894. Intensive studies in this direction give us important information. In the cells of aerobic organisms, free radicals are most often generated from molecular oxygen. It is characterized by the presence of two unpaired electrons with parallel spins in the outer electron shell. Due to this fact, one-electron reduction processes, which do not require spin inversion, are much more likely than two-, three- and four-electron reduction processes <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup>.</p>
      <p>During the pathogenesis of Parkinson’s disease (<abbrev xlink:title="Parkinson’s disease" id="ABBRID0E1AAC">PD</abbrev>)<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup> the production of oxygen-reactive species damages the substantia nigra through lipid peroxidation, protein oxidation, and DNA oxidation <sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup>. This phenomenon seems to be induced mainly by changes in the iron content of the brain, mitochondrial dysfunction <sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup>, monoamine oxidase (<abbrev xlink:title="monoamine oxidase" id="ABBRID0ETBAC">MAO</abbrev>) activation, or even by changes in the antioxidant defense system <sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup>. Much evidence still indicates that exposure to dopaminergic neurotoxins may trigger <abbrev xlink:title="Parkinson’s disease" id="ABBRID0E5BAC">PD</abbrev>-related pathology <sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup>. One of the ways is the effectivity of the oxidizing astrocytic. Another factor is the multiple detrimental oxidative reactions along with the possibility of the formation of reactive oxygen species, including superoxides (O<sup>2--</sup>) in cellular mitochondria and the additional mitochondrial dysfunction and fragmentation along with the oxidative neuronal damage <sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup>. In addition, it should also be considered that in Parkinson’s disease the dopaminergic neurons are extremely susceptible to oxidative stress <sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup>, due to the various oxidants formed from the oxidative changes caused to dopamine after its release from the synaptic vesicles, including H<sub>2</sub>O<sub>2</sub><sup>10</sup>,, O<sub>2</sub> and hydroxyl (OH) and DA-semiquinone radicals’ formation <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup>.</p>
      <p>In healthy dopaminergic neurons, levels of <abbrev xlink:title="reactive oxygen species" id="ABBRID0EJDAC">ROS</abbrev> are strictly controlled by various antioxidative mechanisms involving glutathione (<abbrev xlink:title="glutathione" id="ABBRID0ENDAC">GSH</abbrev>), superoxide dismutase (<abbrev xlink:title="superoxide dismutase" id="ABBRID0ERDAC">SOD</abbrev>) and DJ-1. These processes, however, tend to fail in patients with <abbrev xlink:title="Parkinson’s disease" id="ABBRID0EVDAC">PD</abbrev>.</p>
      <p>Unfortunately, the current treatments for <abbrev xlink:title="Parkinson’s disease" id="ABBRID0E2DAC">PD</abbrev> do not decrease the extent of neurodegeneration,which determines the necessity of the development of new compounds and approaches to novel therapies. Thus, proper agents decreasing the radical’s formation and/or affecting the uncontrolled monoamine oxidase type B effectivity would be a promising strategy in the search for new antiparkinsonian agents.</p>
      <p>The most common <abbrev xlink:title="reactive oxygen species" id="ABBRID0EBEAC">ROS</abbrev> in a biological system are:</p>
      <list list-type="bullet">
        <list-item>
          <p>Superoxide anion (O
                    <sup>2--</sup>) - forms in electron-transport chains and is the precursor of a large number of ROS species. It does not reach far from the site of formation and is deactivated after the addition of another electron and two protons to produce hydrogen peroxide, or by cytosolic and mitochondrial superoxide dismutase 
                     <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup> .
                </p>
        </list-item>
        <list-item>
          <p>Hydrogen peroxide (H
                    <sub>2</sub>O
                    <sub>2</sub>) - reactive and important for the progression of free radical processes, but is not a free radical. However, in the presence of Fe
                    <sup>2+</sup> or other transition valence metals it forms a hydroxyl radical (OH
                    <sup>--</sup>)
                    <sup>10</sup></p>
        </list-item>
        <list-item>
          <p>Hydroxyl radical (OH
                    -) - the most reactive of all ROS and a likely initiator of chain reactions leading to the formation of lipid peroxides and organic radicals. They exist for a very short time and lead to severe oxidative damage. Can arise from a superoxide anion in the presence of hydrogen peroxide (Haber-Weiss reaction) 
                     <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
        </list-item>
        <list-item>
          <p>Organic peroxyl radical (ROO
                    -) - formed after reactions of an oxygen molecule with carbon-based radicals. Peroxyl radicals with carbon-based radicals. Peroxyl radicals are significantly more stable than alkoxy-derived radicals (RO-) and have a half-life of  7 seconds at 37°C. Organic hydroperoxides (RCOOH) are not radicals but unstable and reactive products of peroxyl radicals 
                     <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
        </list-item>
      </list>
      <p>In addition to oxygen, highly reactive forms of nitrogen exist, the most common being nitric oxide (NO-) and peroxynitrite anion (OONO-). NO- is formed by the conversion of L-arginine to citrulline in the presence of nitric oxide synthase (NOS), while O<sup>2-</sup> and NO- are required for peroxynitrite production. A dynamic equilibrium between the formation of reactive oxygen species and the function of protective antioxidant systems (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glucose-6-phosphate dehydrogenase) has been established in the body <sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup>.</p>
    </sec>
    <sec sec-type="﻿Antioxidants" id="SECID0EYFAC">
      <title>﻿Antioxidants</title>
      <p>Antioxidants are substances that neutralize free radicals and remove or reduce their harmful effects. The main types of antioxidants are endogenous and exogenous. Endogenous ones are synthesized in the body <sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>. The most important endogenous antioxidant is glutathione. It is synthesized from three amino acids - glutamine, glycine and cysteine. Glutathione reduces oxidative stress extremely well and has a strong detoxifying effect, improving liver function <sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup>. Exogenous antioxidants are those that the body cannot synthesize and must obtain through diet, supplements or intravenous therapy. This group includes the antioxidants vitamins C, A and E, the elements zinc and selenium and the biologically active compounds of the bioflavonoid and carotene groups <sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup>.</p>
      <p>The best studied antioxidant enzyme systems in the body by which free radicals are eliminated are:</p>
      <list list-type="order">
        <list-item>
          <p>superoxide dismutases (SOD) containing different co-factors: Cu-SOD, Zn-SOD (eukaryotes, humans), Fe-SOD (bacteria and chloroplasts), Mn-SOD (mitochondria) and Ni-SOD (prokaryotes) 
                     <sup>[<xref ref-type="bibr" rid="B14">14</xref>]</sup> .
                </p>
        </list-item>
        <list-item>
          <p>heme-containing enzyme catalase (CAT)
</p>
        </list-item>
        <list-item>
          <p>glutathione peroxidases (GPx): seven isoenzymes such as in humans are GPX1-GPX5
</p>
        </list-item>
        <list-item>
          <p>glutathione reductase (GR)
</p>
        </list-item>
      </list>
      <p><abbrev xlink:title="superoxide dismutase" id="ABBRID0EEHAC">SOD</abbrev> is one of the first defense mechanisms against <abbrev xlink:title="reactive oxygen species" id="ABBRID0EIHAC">ROS</abbrev> and catalyzes the conversion of superoxide radicals to oxygen and hydrogen peroxide <sup>[<xref ref-type="bibr" rid="B14">14</xref>]</sup>. The generated hydrogen peroxide is converted to water and oxygen by CAT. Glutathione peroxidase reduces hydrogen peroxide and hydroperoxides to water and alcohols and glutathione disulfide (GSSG), which is reduced to glutathione (<abbrev xlink:title="glutathione" id="ABBRID0ETHAC">GSH</abbrev>) <sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup> by the enzyme glutathione reductase.</p>
      <p>Peroxiredoxins and the recently discovered sulfiredoxin are also enzymatic antioxidants. Other enzymes that have antioxidant properties, although this is not their primary role, include paraoxonase, glutathione-S transferases <sup>[<xref ref-type="bibr" rid="B15">15</xref>]</sup>, and aldehyde dehydrogenases <sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>.</p>
      <p>The nonenzyme group includes glutathione (<abbrev xlink:title="glutathione" id="ABBRID0EQIAC">GSH</abbrev>) <sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup>, the most abundant antioxidant in most brain cells, thioredoxin (Trx), vitamins A, E, and C, and selenium. <abbrev xlink:title="glutathione" id="ABBRID0E2IAC">GSH</abbrev> reacts with <abbrev xlink:title="reactive oxygen species" id="ABBRID0E6IAC">ROS</abbrev> to generate glutathione disulfide (GSSG) and enters into a cycle with GPx and GR. The hydroxyl radical (-OH) is bound by the endogenous antioxidants glutathione (<abbrev xlink:title="glutathione" id="ABBRID0EDJAC">GSH</abbrev>) and melatonin. Peroxynitrite ion -ONO<sub>2</sub>- and hypochlorite ion - OCl- are bound by glutathione <sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>.</p>
    </sec>
    <sec sec-type="﻿Antioxidants against neurodegenerative diseases" id="SECID0EQJAC">
      <title>﻿Antioxidants against neurodegenerative diseases</title>
      <p>Oxidative stress underlies the pathogenesis of aging and a number of diseases. The brain is particularly sensitive to the effects of free radicals due to high oxygen consumption, the presence of unsaturated fatty acids and reduced activity of oxidation-sensitive endogenous antioxidant systems <sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>. In Alzheimer’s disease, oxidative stress occurs as a result of a disturbance in the balance between endogenous or exogenous overproduction of reactive oxygen species and a decrease in antioxidant defence mechanisms. The study of the sequence of amino acids in Aβ42-peptides allows the specification of their precursor. Its abnormal degradation leads to the formation of Aβ42-peptides, which are involved in amyloidogenesis and neurotoxic adhesive amyloid peptides: 90% Aβ40-peptides and 10% Aβ42-peptides <sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup>.</p>
      <p>The hallmark of neurodegenerative diseases such as Alzheimer, Huntington, Lou Gehrig, Lewy body dementia, multiple sclerosis, and mitochondrial disorders as Friedreich’s ataxia and Leber’s neuropathy, is the progressive malfunction of the nervous system accompanied by atrophy of the structure or function of neurons or the death of neuronal cells <sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup>. The pathogenetic mechanisms of progressive neurological degeneration of the central nervous system are: mitochondrial disorders <sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup>, oxidative stress <sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup>, aggregation of proteins <sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup>, membrane damage, and apoptosis <sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup>.</p>
      <p>Beta-amyloid <sup>[<xref ref-type="bibr" rid="B21">21</xref>]</sup> and alpha-synuclein fragments, as well as hyperphosphorylated tau protein, make up the majority of neurofibrillary tangles in Alzheimer’s disease, or senile plaques <sup>[<xref ref-type="bibr" rid="B21">21</xref>]</sup>. The main strategies for prevention and treatment of Alzheimer’s disease include drugs against amyloid plaques, hyperphosphorylation of tau protein and antioxidants <sup>[<xref ref-type="bibr" rid="B22">22</xref>]</sup>. Antioxidants are of gret importance due to it has been reportei tjtity exhibit properties to eliminate of reactive oxygen species <sup>[<xref ref-type="bibr" rid="B23">23</xref>]</sup>.</p>
      <p>Amyotrophic Lateral Sclerosis is the most severe degenerative disease of the upper and lower motor neurons. Amyotrophic Lateral Sclerosis (Charcot disease) <sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup> is characterized with the severest motor neuron disfunction. Bulbar signs, such as dysarthria (speech disorder) and dysphagia (swallowing difficulty), appeared in the latter stages of the illness. Risk factors are genetic mutations, oxidative stress, glutamate toxicity, lack of trophic growth factors, autoimmune-mediated attack, protein aggregation, inflammation, cytoskeletal abnormalities; viral infection <sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup>. Riluzole is important for treatment of Amyotrophic Lateral Sclerosis <sup>[<xref ref-type="bibr" rid="B25">25</xref>]</sup>.</p>
      <p>Antioxidants are an important additive therapy in treatment of the mentioned neurodegenerative diseases. It has been reported that antioxidant effect exert Vitamins A and E, amino acids, plant extracts, omega-3 unsaturated fatty acids.</p>
      <p>Vitamins A and E are lipophilic molecules and important antioxidants of the group of fat-soluble vitamins acting against lipid peroxidation. Vitamin C (ascorbic acid) is one of the most important water-soluble antioxidants. Selenium is a crucial cofactor for the enzymes GPx and thioredoxin reductase (<abbrev xlink:title="thioredoxin reductase" id="ABBRID0EBNAC">TrxR</abbrev>). All together act and balance the levels of <abbrev xlink:title="reactive oxygen species" id="ABBRID0EFNAC">ROS</abbrev> and <abbrev xlink:title="reactive nitrogen species" id="ABBRID0EJNAC">RNS</abbrev>.</p>
      <p>The flavanol epigallocatechin-3-gallate is the most abundant catechin found in green tea (Camelia sinensis L.) and, due to its antioxidant properties, suppresses cognitive impairment by reducing amyloid-induced mitochondrial dysfunction and neurotoxicity. Isothiocyanates (Moringine) have been isolated from representatives of Brassicacae (Brussels sprouts, cauliflower and broccoli) and are sulfur-containing phytocompounds with protective effects in neurodegenerative diseases due to antioxidant and anti-inflammatory properties <sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup>.</p>
      <p>The following amino acids exhibit antioxidant effect: L-Arginine, L-Histidin, L-Isoleucine, L-Serine, L-Tryptophan and L-Tyrosine. The sulphur-containing amino acids L-Cysteine, N-Acetylsuccinate, L-Methionine, Taurine also possess antioxidant activity. N-Acetylsustteine has antioxidant properties that alleviate symptoms of depression and improve brain function, memory, and the ability to acquire new cognitions in the aged. Contained in garlic extract, S-allyl-L-Cysteine suppresses pathological cascades associated with synaptic degeneration and neuroinflammatory pathways <sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup>.</p>
      <p>Taurine is an antioxidant that provides magnesium and calcium access to brain cells and stimulates nerve cell function. Phosphatidylserine exhibits antioxidant activity in lipid peroxidation and activates enzyme activity and membrane function of nerve cells and is particularly effective when combined with Omega-3 unsaturated fatty acids.</p>
      <p>Protective antioxidant effects in Alzheimer’s disease are exerted by extracts of Melissa officinalis L. (Caffeic acid, Ferulic acid, Rosmarinic acid), Rosmarinus officinalis L. (Carnosic acid, Ferulic acid, Rosmarinic acid, Hesperidin), Salvia officinalis L. (Carnosic acid, Rosmarinic acid), Lavandula angustifolia L., Daucus carota L., Hypericun perforatum L. (Quercitrin), Withania somnifera (stimulates superoxide dismutase, catalase and glutathione peroxidase activity) <sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup>.</p>
      <p>Some alkaloids show a trend of efficacy in the treatment of behavioral symptoms, with proven neuroprotective properties in experimental models of Alzheimer’s disease: Galantamine, Nicotine, Morphine, Caffeine, Berberine, Huperzine <sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup>.</p>
      <p>Galantamine is appropriate for therapy of treatment of Alzheimer <sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup> due to exerts antioxidant and neuroprotective effect <sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup>. In the experiments, the antioxidant activity of Galantamine hydrobromide was investigated in vitro using a Luminol-dependent chemiluminescence method. Galantamine exerted a neuroprotective effect by lowering oxidative neuronal damage by binding reactive oxygen species: -O<sup>2</sup>- (superoxide), -O<sub>2</sub><sup>2</sup>- (peroxide), -OH (hydroxyl), RO- (alkoxy) <sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup>.</p>
      <p>Omega-6 unsaturated fatty acids: linoleic, γ-linolenic, arachidonic (eicosatetraenoic) are grouped as vitamin F and contained in vegetable oils. Linoleic acid is the main representative of Omega-6 unsaturated fatty acids, present in nuts, seeds and vegetable oils. Omega-6 unsaturated fatty acids in small doses are necessary, but in large amounts counteract Omega-3 unsaturated fatty acids, even if Omega-3 unsaturated fatty acids are taken in sufficient amounts. Omega-3 unsaturated fatty acids reduce inflammation by inhibiting the conversion of arachidonic acid to proinflammatory factors; by suppressing other proinflammatory cytokines: tumor necrosis factor α-interferon, γ-interferon, interleukin 1 (Il-1),Il-2 ,Il-1β; by limiting T-cell proliferation and inhibiting leukocyte migration. Omega-3 unsaturated fatty acids may directly limit pathology in AD <sup>[<xref ref-type="bibr" rid="B30">30</xref>]</sup>.</p>
    </sec>
    <sec sec-type="﻿Conclusion" id="SECID0EXPAC">
      <title>﻿Conclusion</title>
      <p>Oxidative stress is a risk factor for the developmene of neurodegenerative diseases suxh as Parkinson’s, Alzheimer’s, Huntington’s and Amyotrophic Lateral Sclerosis. An important role in prevention and treatment of neurodegenerative diseases. are antioxidants as Vitamins A and E, flavonoids and alkaloids from plant extracts, aminoacids, omega-3 unsaturated fatty acids.</p>
      <p>Plant extracts from Lavandula angustifolia L., Melissa officinalis L., Rosmarinus officinalis L., Salvia officinalis L., Hypericun perforatum L., Withania somnifera are described to possess antioxidant activity and can help for protection against Alzheimer’s disease. Galantamine is appropriate for therapy of treatment of Alzheimer due to exerts antioxidant and neuroprotective effect. Drug Riluzole exhibits effects against different diseases due to protects against memory loss, has antidepressant-like qualities, and is used to treat chronic schizophrenia, autistic disorder, Parkinson’s disease, and hereditary ataxia as an adjuvant therapy to Risperidone.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="﻿Additional information" id="SECID0E5PAC">
      <title>﻿Additional information</title>
      <p>
        <bold>Conflict of interest</bold>
      </p>
      <p>The authors have declared that no competing interests exist.</p>
      <p>
        <bold>Ethical statements</bold>
      </p>
      <p>The authors declared that no clinical trials were used in the present study.</p>
      <p>The authors declared that no experiments on humans or human tissues were performed for the present study.</p>
      <p>The authors declared that no informed consent was obtained from the humans, donors or donors’ representatives participating in the study.</p>
      <p>The authors declared that no experiments on animals were performed for the present study.</p>
      <p>The authors declared that no commercially available immortalised human and animal cell lines were used in the present study.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>No funding was reported.</p>
      <p>
        <bold>Author contributions</bold>
      </p>
      <p>All authors have contributed equally.</p>
      <p>
        <bold>Author ORCIDs</bold>
      </p>
      <p>Stefka Ivanova <ext-link xlink:href="https://orcid.org/0000-0003-3324-5840" ext-link-type="uri" xlink:type="simple">https://orcid.org/0000-0003-3324-5840</ext-link></p>
      <p>Danka Obreshkova <ext-link xlink:href="https://orcid.org/0000-0001-9960-0556" ext-link-type="uri" xlink:type="simple">https://orcid.org/0000-0001-9960-0556</ext-link></p>
      <p>Petar Atanasov <ext-link xlink:href="https://orcid.org/0009-0006-8337-2089" ext-link-type="uri" xlink:type="simple">https://orcid.org/0009-0006-8337-2089</ext-link></p>
      <p>Boris Mladenov <ext-link xlink:href="https://orcid.org/0000-0003-4219-1231" ext-link-type="uri" xlink:type="simple">https://orcid.org/0000-0003-4219-1231</ext-link></p>
      <p>Venceslava Atanasova <ext-link xlink:href="https://orcid.org/0000-0000-0000-0000" ext-link-type="uri" xlink:type="simple">https://orcid.org/0000-0000-0000-0000</ext-link></p>
      <p>Adel Ibrahim <ext-link xlink:href="https://orcid.org/0000-0000-0000-0000" ext-link-type="uri" xlink:type="simple">https://orcid.org/0000-0000-0000-0000</ext-link></p>
      <p>
        <bold>Data availability</bold>
      </p>
      <p>All of the data that support the findings of this study are available in the main text or Supplementary Information.</p>
    </sec>
    <ref-list>
      <title>﻿References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple">1. Pisoschi A, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. E J Med Chem, 2015;97:55-74. <ext-link xlink:href="10.1016/j.ejmech.2015.04.040" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2015.04.040</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple">2. Jena AB, Samal RR, Bhol NK, Asim K. Duttaroy. Cellular red-ox system in health and disease: the latest update. Biomed Pharmacother. 2023;162:114606. <ext-link xlink:href="10.1016/j.biopha.2023.114606" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.biopha.2023.114606</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple">3. Sharma C, Kim SR. Linking oxidative stress and proteinopathy in Alzheimer’s disease. Antioxidants (Basel). 2021;10(8):1231. <ext-link xlink:href="10.3390/antiox10081231" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/antiox10081231</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple">4. Juan CA, Pérez de la Lastra, JM, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci, 2021;22(9):4642. <ext-link xlink:href="10.3390/ijms22094642" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/ijms22094642</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple">5. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson’s disease. The Lancet, 2024;403(10423):293-304. <ext-link xlink:href="10.1016/S0140-6736(23)01478-2" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/S0140-6736(23)01478-2</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple">6. Trist, B. G., Hare, D. J., &amp; Double, K. L. (2019). Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging cell, 18(6), e13031. <ext-link xlink:href="10.1111/acel.13031" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/acel.13031</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple">7. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J 2012;31(14):3038–3062 <ext-link xlink:href="10.1038/emboj.2012.170" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/emboj.2012.170</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple">8. Segura-Aguilar J, Kostrzewa RM. Neurotoxin mechanisms and processes relevant to Parkinson’s disease: an update. Neurotox Res, 2015;27:328-354. <ext-link xlink:href="10.1007/s12640-015-9519-y" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s12640-015-9519-y</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple">9. Guo JD, Zhao X, Li Y, Li GR, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease. Int J. Mol Med, 2018;41(4):1817-1825. <ext-link xlink:href="10.3892/ijmm.2018.3406" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3892/ijmm.2018.3406</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple">10. Pravda. Hydrogen peroxide and disease: towards a unified system of pathogenesis and therapeutics. Molecul Med, 2020;26(1):41. <ext-link xlink:href="10.1186/s10020-020-00165-3" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1186/s10020-020-00165-3</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple">11. Flieger J, Flieger W, Baj J, Maciejewski, R. Antioxidants: classification, natural sources, activity/capacity measurements, and usefulness for the synthesis of nanoparticles. Materials, 2021;14(15): 4135. <ext-link xlink:href="10.3390/ma14154135" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/ma14154135</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple">12. Liu T, Sun L, Zhang Y, Wang Y, Zheng J. Imbalanced GSH/ROS and sequential cell death. J Biochem Mol Toxicol. 2022 Jan;36(1):e22942. <ext-link xlink:href="10.1002/jbt.2294" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/jbt.2294</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple">13. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nature Rev Drug Discov, 2021;20(9):689-709. <ext-link xlink:href="10.1038/s41573-021-00233-1" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/s41573-021-00233-1</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple">14. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol, 2018;217(6):1915-1928. <ext-link xlink:href="10.1083/jcb.201708007" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1083/jcb.201708007</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple">15. Mazari AMA, Zhang L, Ye ZW, Zhang J, Tew KD, Townsend DM. The multifaceted role of Glutathione S-transferases in health and disease. Biomolecules. 2023;13(4):688. <ext-link xlink:href="10.3390/biom13040688" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/biom13040688</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple">16. Naskar S, Gour N. Realization of Amyloid-like aggregation as a common cause for pathogenesis in diseases. Life (Basel), 2023;13(7):1523. <ext-link xlink:href="10.3390/life13071523" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/life13071523</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple">17. Thompson LM. Neurodegeneration: a question of balance. Nature, 2008;45(7188):707-708. <ext-link xlink:href="10.1038/452707a" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/452707a</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple">18. Di Mauro S, Schon EA. Mitochondrial disorders in the nervous system. Annual Rev Neurosci, 2008;31(1):91-123. <ext-link xlink:href="10.1146/annurev.neuro.30.051606.094302" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1146/annurev.neuro.30.051606.094302</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple">19. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006;443(7113):787-95. <ext-link xlink:href="10.1038/nature05292" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/nature05292</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple">20. Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecul Med, 2003;4(1-2):21-36. <ext-link xlink:href="10.1385/NMM:4:1-2:21" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1385/NMM:4:1-2:21</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple">21. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurol. 2004;62(11):1984-9. <ext-link xlink:href="10.1212/01.WNL.0000129697.01779.0A" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1212/01.WNL.0000129697.01779.0A</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple">22. Tsvetkova D, Obreshkova D. Modern approaches and strategies for prevention and therapeutic influence of Alzheimer’s disease. Int J Pharm Res Allied Sci. 2019;8(1):1-16.</mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple">23. He, L., He, T., Farrar, S., Ji, L., Liu, T., &amp; Ma, X. (2017). Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cellular Physiology and Biochemistry, 44(2), 532-553. <ext-link xlink:href="10.1159/000485089" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1159/000485089</ext-link></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple">24. Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Ienco EC, Alessi R, et al. Strategies for clinical approach to neurodegeneration in Amyotrophic Lateral Sclerosis. Arch Ital Biol. 2011;149(1):151-67. <ext-link xlink:href="10.4449/aib.v149i1.1267" ext-link-type="doi" xlink:type="simple">https://doi.org/10.4449/aib.v149i1.1267</ext-link></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation xlink:type="simple">25. Fehlings MG, Nakashima H, Nagoshi N, Chow DSL, Grossman RG, Kopjar B. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord, 2016;54(1):8-15. <ext-link xlink:href="10.1038/sc.2015.95" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/sc.2015.95</ext-link></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation xlink:type="simple">26. Ding H, Reiss AB, Pinkhasov A, Kasselman LJ. Plants, plants, and more plants: plant-derived nutrients and their protective roles in cognitive function, Alzheimer’s disease, and other dementias. Medicina, 2022;58(8):1025. <ext-link xlink:href="10.3390/medicina58081025" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/medicina58081025</ext-link></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation xlink:type="simple">27. Liu J, Zhang D, Zhu Y, Wang Y, He S, Zhang T. Enhancing the in vitro antioxidant capacities via the interaction of amino acids. Emirates J Food Agricult (EJFA), 2018;30(3).234-231. <ext-link xlink:href="10.9755/ejfa.2018.v30.i3.1641" ext-link-type="doi" xlink:type="simple">https://doi.org/10.9755/ejfa.2018.v30.i3.1641</ext-link></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation xlink:type="simple">28. Tsvetkova D, Obreshkova D, Ivanova St, Hadjieva B. Benefits of acethylcholin-esterase inhibitor Galantamine in treatment of Alzheimer disease and instrumental methods for its analysis in medicinal plants. J Med Pharm Allied Sci. 2016;5(7):99-116.</mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation xlink:type="simple">29. Tsvetkova D, Obreshkova D, Zheleva-Dimitrova D, Saso L. Antioxidant activity of Galanthamine and some of it’s derivatives. Curr Med Chem, 2013;20(36):4595-608. <ext-link xlink:href="10.2174/09" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2174/09</ext-link></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation xlink:type="simple">30. Heshmati J, Morvaridzadeh M, Maroufizadeh S, Akbari A, Yavari M, Amirinejad A, Maleki-Hajiagha A , Sepidarkish, M. (2019). Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials. Pharmacological research, 2019;149, 104462. <ext-link xlink:href="10.1016/j.phrs.2019.104462" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.phrs.2019.104462</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
